AC Immune reports favorable Phase 1 data for ACI-19764

AC Immune SA (NASDAQ: ACIU ) reported favorable interim Phase 1 clinical trial results for ACI-19764, an orally administered drug designed to target the NLRP3 inflammasome. The clinical-stage biopharmaceutical company primarily focuses on developing targeted therapies for neurodegenerative conditions. The European study evaluates the drug’s safety, tolerability, and pharmacokinetics in healthy volunteers. Early findings indicate that ACI-19764 remains safe and well-tolerated across single and multiple ascending dose groups.

The company tested doses up to 20mg daily, noting a serum half-life exceeding 30 hours. Researchers observed no serious adverse events or treatment withdrawals during this period. Read Also: FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics Brain Penetration And Efficacy Signals The study showed clear evidence of brain penetration through cerebrospinal fluid exposure. Daily doses of 10mg or less reached pharmacokinetic concentrations above the IC90 threshold.

Furthermore, a blinded review of whole blood assays confirmed that the drug successfully inhibited IL-1beta release in a dose-dependent manner. ACI-19764 aims to block pro-inflammatory factors and lower chronic inflammation, which drives disease progression across multiple metabolic, inflammatory, and neurological disorders. Phase 1b Expansion and Future Milestones Following these positive safety outcomes, the trial advanced to a Phase 1b cohort. Medical professionals have started dosing patients at risk for cardiovascular disease.

These participants exhibit elevated high-sensitivity C-reactive protein levels, alongside obesity or type 2 diabetes. Patient recruitment remains active, and the company anticipates releasing initial findings for this group before the year ends. Backed by robust preclinical toxicity data, the ACI-19764 program expects to yield additional clinical updates in the first half of 2027. ” Martin Zügel, interim CEO of AC Immune, commented.

We believe ACI-19764 has the potential to be a powerful NLRP3 inhibitor, and we look forward to further exploring its therapeutic potential,” Zügel further added. 47 at the time of publication on Thursday, according to Pro data. Read Also: Elon Musk Says SPCX Could Make History in the ‘Next Few Months’ With First-Ever Starship Tower Catch Image via Shutterstock